28. Consolidation scope
|
|
|
|
|
|
|
Ownership interest |
|
||||
|
|
|
|
|
Place of |
|
As at December 31, |
|
||||
|
Legal Entity |
|
Principal activity |
|
incorporation |
|
2017 |
|
2016 |
|
2015 |
|
|
TiGenix Romeinse straat 12, Box 2 3001 Leuven |
|
Biopharmaceutical company |
|
Belgium |
|
100 |
% |
100 |
% |
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TiGenix SAU Calle Marconi 1, Parque Tecnológico de Madrid Tres Cantos 28760 Madrid |
|
Biopharmaceutical company |
|
Spain |
|
100 |
% |
100 |
% |
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Coretherapix SLU Calle Marconi 1, Parque Tecnológico de Madrid Tres Cantos 28760 Madrid |
|
Biopharmaceutical company |
|
Spain |
|
100 |
% |
100 |
% |
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TiGenix Inc 1209 Orange Street Wilmington, Delaware |
|
Biopharmaceutical company |
|
U.S.A. |
|
100 |
% |
100 |
% |
100 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TiGenix US, Inc 1209 Orange Street Wilmington, Delaware |
|
Biopharmaceutical company |
|
U.S.A. |
|
100 |
% |
— |
|
— |
|